Santersus AG announces the successful completion of their first in human clinical trials relating to Sepsis and COVID-19.
- First trial started in Feb 2021 in Sepsis/COVID-19
- Recruitment completed in September 2021 with 10 patients
- Interim analysis showed safe, easy to apply, confirmed the reduction in NETs with a strong temporal association with clinical improvement